Impact of Adjunct Immunotherapy with Multi-herbal Supplement Dzherelo (Immunoxel) on Treatment Outcomes in End-stage TB/HIV Patients
- *Corresponding Author:
- Dr. Galyna A. Kutsyna MD,
PhD, Luhansk State Medical University,
50-years of Defense of Luhansk street Luhansk 91045, Ukraine,
Tel : +380508093822,
E-mail : [email protected]
Received Date: September 12, 2009; Accepted Date: December 30, 2009; Published Date: December 30, 2009
Citation: Arjanova OV, Prihoda ND, Yurchenko LV, Sokolenko NI, Vihrova LA, et al. (2009) Impact of Adjunct Immunotherapy with Multi-herbal Supplement Dzherelo (Immunoxel) on Treatment Outcomes in End-stage TB/HIV Patients. J Antivir Antiretrovir 1: 086-088. doi: 10.4172/jaa.1000013
Copyright: © 2009 Arjanova OV et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Prognosis for TB/HIV co-infection is very unfavourable. In terminally-ill patients treatment options are often limited to palliative care. In our salvage, 2-month therapy of 40 late-stage TB/HIV patients we administered to half of the patients TB drugs along with over-the-counter botanical immunomodulator Dzherelo (Immunoxel). Despite best possible care 6 patients had died. Remaining 14 patients experienced marked clinical improvements and one patient was discharged due to full recovery. Among 20 matched subjects on conventional TB regimen, 12 died and only one was slightly better-off. These results indicate that Dzherelo might reduce mortality (P=0.055) and improve significantly the quality of life (P=0.00002). Improvement in quality of life is also supported by substantial weight gain (mean/median 3.3/4 kg) in much higher proportion of patients than among those who received TB drugs only, i.e., 16 vs. 1 (P=0.000001). At the end of two months 13 (65%) patients became sputum smear negative versus only one individual (5%) in ATT group (P=0.00007). These results suggest that adjuvant immunotherapy improves significantly therapy outcome and reduces mortality. Larger study is warranted to confirm the benefit of Dzherelo.